Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
FLOX plus Erbitux as first-line treatment in metastatic colorectal cancer with wild-type KRAS
2007-007834-21Phase 2Completed
- Sponsor
- University Hospital Odense
- Start
- Feb 2008
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of cetuximab in metastatic colon cancer (mCRC), sponsored by University Hospital Odense. Primary endpoint: Objective response rate. Started Feb 2008; status: completed.
02
Drugs
cetuximab
03
Conditions
metastatic colon cancer (mCRC)
Beyond the preview
Go deeper on 2007-007834-21.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2007-007834-21.